Eli Lilly

LLY

Market cap $657B

Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI picks.

Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-loss sector. Eli Lilly's move into the obesity drug market is reshaping the global pharma landscape.

@coryrenauer Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure.

They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.

Trading is quiet in Eli Lilly and Co  LLY on Thursday. The stock has stalled out at a resistance level.

Eli Lilly's explosive growth is driven by GLP-1 drugs Mounjaro and Zepbound, with tirzepatide becoming a historic best-seller in obesity and diabetes. President Trump's aggressive drug pricing reforms create significant uncertainty, but Lilly is adapting by raising overseas prices and expanding direct-to-consumer efforts. Despite near-term volatility and premium valuation, Lilly's GLP-1 franchise could generate $60bn+ annually, supporting a potential $1 trillion market cap.

Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron's convenience, scalability, and potential dual-indication label position it as a key driver for Eli Lilly's revenue diversification and premium valuation. Despite payer coverage and tolerability challenges, the massive eligible population and orforglipron's advantages should drive exponential sales growth.

In 2018, Apple became the first publicly traded company to reach a $1 trillion market capitalization. Several more have joined that club since, but it remains highly exclusive, with fewer than 10 members among the thousands of stocks trading on equity markets.

Eli Lilly and Company is a leader in cardiometabolic medicine, with strong R&D, innovative obesity and diabetes drugs, and expanding oncology and neuroscience portfolios. Recent clinical wins, especially for oral GLP-1 orforglipron, and robust financials support continued growth, but valuation remains a key concern. Despite premium pricing, aggressive R&D investment justifies Lilly's growth prospects, though political and payer risks could impact future performance.

According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling all 12,036 shares in Q2 2025.